Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: "Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial" by Bocchi et al

Affiliations

• ¹ Instituto do Coração (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
• ² Cordoba National University, Instituto DAMIC/Fundación Rusculleda, Córdoba, Argentina.
• ³ Clinica Shaio, Bogotá, Colombia.
• ⁴ Novartis Pharma, São Paulo, Brazil.
• ⁵ Novartis Pharma, Basel, Switzerland.
• ⁶ Institut de Cardiologie de Montréal, Université de Montréal, Montréal, Canada.
• ⁷ Department of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
• ⁸ Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
• ⁹ National Heart and Lung Institute, Imperial College London, London, UK.
• ¹⁰ Medical University of South Carolina and Ralph H. Johnson Veterans Administration Medical Center, Charleston, SC, USA.
• ¹¹ Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.
• ¹² British Heart Foundation Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK.